logo

EXOZ

eXoZymes·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

EXOZ fundamentals

eXoZymes (EXOZ) released its earnings on Nov 13, 2025: revenue was -- (YoY 0.00%), beat estimates; EPS was -0.27 (YoY 0.00%), missed estimates.
Revenue / YoY
--
0.00%
EPS / YoY
-0.27
0.00%
Report date
Nov 13, 2025
EXOZ Earnings Call Summary for Q3,2025
  • Three Key Products Launched: NCT (metabolic agent), cannabinoids (non-intoxicating), and Sandeline (fragrance/pharma).
  • NCT Production Milestone: 90%+ yield, spinout NCTX targeting 2026 launch.
  • Financial Health: $5.1M cash, $2.52M Q3 expenses, exploring non-dilutive funding.
  • Cannabinoid Opportunity: Federal law separation of THC and non-intoxicants aligns with eXoZymes' precise manufacturing.
  • Strategic Focus: Capital-light model, avoiding early partnerships to maximize value.
EPS
Revenue

Revenue & Expenses

Key Indicators

eXoZymes (EXOZ) key financial stats and ratios, covering profitability, financial health, and leverage.
eXoZymes (EXOZ)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
eXoZymes (EXOZ)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
eXoZymes (EXOZ)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does eXoZymes (EXOZ) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track eXoZymes (EXOZ) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield